Cargando…
MicroRNA‐130a, a Potential Antifibrotic Target in Cardiac Fibrosis
BACKGROUND: Cardiac fibrosis occurs because of disruption of the extracellular matrix network leading to myocardial dysfunction. Angiotensin II has been implicated in the development of cardiac fibrosis. Recently, microRNAs have been identified as an attractive target for therapeutic intervention in...
Autores principales: | Li, Li, Bounds, Kelsey R., Chatterjee, Piyali, Gupta, Sudhiranjan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721768/ https://www.ncbi.nlm.nih.gov/pubmed/29114000 http://dx.doi.org/10.1161/JAHA.117.006763 |
Ejemplares similares
-
MicroRNAs: New Players in the Pathobiology of Preeclampsia
por: Bounds, Kelsey R., et al.
Publicado: (2017) -
Deficiency of MicroRNA miR‐1954 Promotes Cardiac Remodeling and Fibrosis
por: Chiasson, Valorie, et al.
Publicado: (2019) -
Antifibrotic therapies to control cardiac fibrosis
por: Fan, Zhaobo, et al.
Publicado: (2016) -
HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary
fibrosis
por: Lyu, Xing, et al.
Publicado: (2019) -
Impact of microRNA-130a on the neutrophil proteome
por: Pedersen, Corinna Cavan, et al.
Publicado: (2015)